|
Download PDF
|
Commercial Insight: Community Antibacterials - Pipelines wither
as generic tidal wave takes its toll
Introduction
Datamonitor research points to this sector, beleaguered by
patent expiries, barriers to market entry and uptake, becoming
increasingly inclement towards branded drugs. Generic incursion
has taken a heavy toll on the market at a number of levels. The
volume of key brands facing generic competition makes it even
harder for remaining products to court large revenues in the
community sector.
Scope
-
Analysis of the retail market for antibacterials across Japan,
US, France, Italy, Germany Spain and the UK
-
Product by product analysis of the key marketed brands with a
10 year forecast
-
Assessment of key developments shaping the sector, e.g.,
generic substitution
-
Discussion of opportunities and threats on a general, regional
and national level
Highlights
The community market for antibiotics is declining at a CAGR of
-3% over the 2003 07 period. This is the mark of a sector
already saturated by generic product. Over the 2003 07 period
generic share of the market has grown from 30% of the market, to
40% of seven major market revenues, and from 56% to 65% of
volume share.
Aside from the substantial difference in market sizes between
the US, Japan and the five major EU markets, the nature of
community antibacterial sales across the three territories
varies greatly. For example, market shares fluctuate
substantially depending on whether volume or value statistics
are considered.
In 2007, the US accounted for a much higher proportion of value
share of the market (57%) than volume share (47%), while
relatively speaking, the 5EU accounted for a much lower
proportion of value share (27%) by comparison to volume share
(37%)pointing to substantial differences in the average cost per
standard unit.
Reasons to Purchase
-
Learn about the extent of the still expanding generic
domination of the sector and how to counter it
-
Assess the regional and national differences in terms of class
and brand preferences and where the opportunities lie
-
Review the changes in class sales that signal the shift in
prescribing practices
View
Table Of Contents >
|
